Ousia - great post. Well thought out.
PI-88 Trials in Taiwan are a much more 'straightforward' proposition then the Multi Country Phase III undertaking.
Recruitment rates are very difficult to predict in terms of such global Trial. Liver Cancer is a much more prevalent disease in Asia as I understand matters, and therefore recruitment rates are more certain there.
A new dawn for Progen!
interesting times ahead, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
